Physician profile
Melissa Fickey Vilardebo
NPI 1700951985
$85,543.47
in general payments reported to CMS, 2019-2025
45 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,067 · 2020: $10K · 2021: $2,330 · 2022: $17K · 2023: $5,278 · 2024: $17K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $18K · Travel and Lodging: $6,763 · Education: $86.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,275.00 |
| Food and Beverage | $17,939.26 |
| Travel and Lodging | $6,762.81 |
| Education | $86.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $57,613.42 | 2019-2025 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $7,948.33 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $3,054.23 | 2021-2025 | Vraylar |
| Tris Pharma INC | $1,491.91 | 2019-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $1,278.85 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,264.36 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,083.69 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $961.92 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $929.75 | 2019-2025 | Trintellix |
| Corium, LLC | $893.66 | 2021-2025 | Azstarys |
| Neos Therapeutics, Lp | $888.96 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Ironshore Pharmaceuticals INC. | $823.34 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $723.46 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $711.78 | 2021-2025 | Aristada, Lybalvi |
| Almatica Pharma LLC | $654.62 | 2021-2025 | Loreev Xr, Gralise, Teriparatide |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $610.34 | 2019-2022 | |
| Noven Therapeutics, LLC | $594.27 | 2023-2025 | Xelstrym, Secuado |
| Validus Pharmaceuticals LLC | $571.21 | 2019-2024 | Equetro |
| Axsome Therapeutics, INC. | $539.21 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $309.91 | 2025 | |
| Allergan, INC. | $286.08 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $258.76 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $239.27 | 2019-2022 | |
| Bausch Health US, LLC | $228.68 | 2019-2025 | Aplenzin |
| Harmony Biosciences LLC | $199.91 | 2022-2024 | Wakix |
| Idorsia Pharmaceuticals US INC | $198.58 | 2022-2025 | Quviviq, Quviviq |
| Eisai INC. | $151.30 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $149.61 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $118.06 | 2019-2021 | |
| Owp Pharmaceuticals, INC. | $117.13 | 2019-2025 | Subvenite, Lamotrigine |
| Arbor Pharmaceuticals, INC. | $77.78 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $71.37 | 2019-2024 | Relexxii |
| Merck Sharp & Dohme LLC | $71.10 | 2020-2022 | |
| Sage Therapeutics, LLC | $69.46 | 2021-2025 | Zurzuvae |
| Rhodes Pharmaceuticals L.P. | $51.84 | 2019 | |
| Avion Pharmaceuticals | $49.55 | 2023 | Methylphenidate Hydrochloride |
| Novo Nordisk INC | $46.83 | 2019-2020 | |
| Livanova USA, INC. | $44.25 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $38.17 | 2025 | Jornay Pm |
| Alfasigma USA, INC. | $32.92 | 2020-2022 | |
| Shire North American Group INC | $29.55 | 2019 | |
| Noven Pharmaceuticals, INC. | $23.14 | 2024 | Xelstrym |
| Lilly USA, LLC | $16.53 | 2025 | Zepbound |
| Currax Pharmaceuticals LLC | $14.39 | 2021 | |
| Aytu Biopharma, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Vilardebo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.